A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Lipoprotein(a)

In brief

Researchers designed a trial medicine called MK-7262 to lower levels of Lp(a) in the blood. Researchers want to learn about giving MK-7262 with another trial medicine called enlicitide (also known as MK-0616 or enlicitide decanoate). Enlicitide is in a group of medicines that lower the amount of low-density lipoprotein cholesterol (LDL-C). The goals of this trial are to evaluate: * if MK-7262 and enlicitide taken together work better than placebo at lowering Lp(a) and LDL-C levels in the blood * if MK-7262 alone works better than placebo at lowering Lp(a) levels in the blood * the safety and tolerability of taking MK-7262 and enlicitide alone and together

Key facts

Study ID

NCT07614984

Run by

Merck Sharp & Dohme LLC

People needed

750

Starts

2026-06-30

Expected to finish

2027-10-12

Last updated by the study team

2026-08-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The main inclusion criteria include but are not limited to the following:
• Has Lp(a) ≥ 150 nmol/L
• Is receiving an optimized and stable dose of statin for ≥ 30 days with no planned additions, dose changes, or discontinuations through the duration of the study

You may not qualify if…

• The main exclusion criteria include but are not limited to the following:
• Has a history of homozygous familial hypercholesterolemia (FH), compound heterozygous FH, or double heterozygous FH
• Has a history of class IV heart failure, severe ventricular systolic dysfunction, uncontrolled ventricular arrhythmia, markedly prolonged corrected QT interval, untreated hypertension, or a recent coronary, cerebrovascular, or peripheral ischemic event or arterial revascularization
• Has human immunodeficiency virus infection, unless the infection is controlled (i.e. undetectable viral load)
• Has an active hepatitis C virus infection or active or chronic hepatitis B virus infection
• Has a history of nephrotic syndrome
• Has severe renal insufficiency
• Has received certain therapies in the prohibited timeframe as specified in the protocol
• Has active or chronic hepatobiliary or hepatic disease
• Has poorly controlled Type 1 or Type 2 diabetes

Where it is running

• Advanced Cardiovascular - Alexander City ( Site 0158) — Alexander City, Alabama, United States (enrolling)
• AMR Clinical Mobile ( Site 0149) — Mobile, Alabama, United States (enrolling)
• National Heart Institute ( Site 0113) — Beverly Hills, California, United States (enrolling)
• Headlands Research CTR Lincoln ( Site 0127) — Lincoln, California, United States (enrolling)
• Chase Medical Research, LLC ( Site 0163) — Waterbury, Connecticut, United States (enrolling)
• Soffer Health Institute ( Site 0123) — Hollywood, Florida, United States (enrolling)
• Westside Center for Clinical Research ( Site 0161) — Jacksonville, Florida, United States (enrolling)
• Inpatient Research Clinic ( Site 0110) — Miami Lakes, Florida, United States (enrolling)
• Clinical Research Trials of Florida ( Site 0101) — Tampa, Florida, United States (enrolling)
• Conquest Research LLC ( Site 0140) — Winter Park, Florida, United States (enrolling)
• Flourish Research - Bowie ( Site 0106) — Bowie, Maryland, United States (enrolling)
• Velocity Clinical Research Rockville ( Site 0146) — Rockville, Maryland, United States (enrolling)
• Arcturus Healthcare , PLC, Troy Internal Medicine Research Division ( Site 0132) — Troy, Michigan, United States (enrolling)
• Montana Medical Research, Inc. ( Site 0156) — Missoula, Montana, United States (enrolling)
• New Mexico Clinical Research & Osteoporosis Center ( Site 0119) — Albuquerque, New Mexico, United States (enrolling)
• Laurelton Heart Specialist PC ( Site 0155) — Rosedale, New York, United States (enrolling)
• Velocity Clinical Research, Durham ( Site 0145) — Durham, North Carolina, United States (enrolling)
• Remington-Davis, Inc. ( Site 0107) — Columbus, Ohio, United States (enrolling)
• Holston Medical Group ( Site 0117) — Kingsport, Tennessee, United States (enrolling)
• DM Clinical Research ( Site 0115) — Tomball, Texas, United States (enrolling)
• Carient Heart & Vascular - Manassas ( Site 0165) — Manassas, Virginia, United States (enrolling)
• Rainier Clinical Research Center ( Site 0116) — Renton, Washington, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.